Cargando…
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
BACKGROUND AND PURPOSE: Acamprosate is an anti‐craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety an...
Autores principales: | Ho, Ming‐Fen, Zhang, Cheng, Wei, Lixuan, Zhang, Lingxin, Moon, Irene, Geske, Jennifer R., Skime, Michelle K., Choi, Doo‐Sup, Biernacka, Joanna M., Oesterle, Tyler S., Frye, Mark A., Seppala, Marvin D., Karpyak, Victor M., Li, Hu, Weinshilboum, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177536/ https://www.ncbi.nlm.nih.gov/pubmed/35016259 http://dx.doi.org/10.1111/bph.15795 |
Ejemplares similares
-
TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020) -
Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022) -
Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism
por: Ho, Ming-Fen, et al.
Publicado: (2022) -
Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
por: Hinton, David J., et al.
Publicado: (2017) -
PM307. Untargeted Global Metabolomics Reveals Metabolites Associated with Acamprosate Treatment Outcome
por: Ho, Ada, et al.
Publicado: (2016)